Grail
Lillys Investigational Gene Therapy Restores Hearing in First Treated Patient
Hearing, Treating, gene therapy, AK-OTOF
Sarepta shares PhII data for next-gen exon skipping drug, but regulatory pathway is unclear
Regulatory Pathway, Sarepta, next-generation exon-skipping drug, United States Food and Drug Administration, Approved, Muscular Dystrophy, Duchenne, gene therapy, Sarepta’s gene therapy